通过代谢组学分析鉴定双相情感障碍患者接受情绪稳定剂治疗的外周生物标志物:一项探索性研究。

IF 3.7 2区 医学 Q1 CLINICAL NEUROLOGY
Cristina Piras, Claudia Pisanu, Martina Spada, Anna Meloni, Donatella Congiu, Vanessa Palmas, Giovanni Severino, Raffaella Ardau, Caterina Chillotti, Martina Contu, Pasquale Paribello, Marco Pinna, Federico Suprani, Maria Del Zompo, Bernardo Carpiniello, Aldo Manzin, Mirko Manchia, Luigi Atzori, Alessio Squassina
{"title":"通过代谢组学分析鉴定双相情感障碍患者接受情绪稳定剂治疗的外周生物标志物:一项探索性研究。","authors":"Cristina Piras, Claudia Pisanu, Martina Spada, Anna Meloni, Donatella Congiu, Vanessa Palmas, Giovanni Severino, Raffaella Ardau, Caterina Chillotti, Martina Contu, Pasquale Paribello, Marco Pinna, Federico Suprani, Maria Del Zompo, Bernardo Carpiniello, Aldo Manzin, Mirko Manchia, Luigi Atzori, Alessio Squassina","doi":"10.1093/ijnp/pyaf071","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Bipolar disorder (BD) is mainly treated with mood stabilizers, among which lithium represents the gold standard. Despite its high clinical efficacy, the molecular players involved in lithium response and non-response remain partly unclear. Therefore, the identification of peripheral biomarkers would significantly improve the management of pharmacological interventions in BD.</p><p><strong>Objective and design: </strong>In this study we sought to investigate the blood metabolome in patients with BD to identify biosignatures of treatment with different mood stabilizers as well as possible biomarkers of response to lithium.</p><p><strong>Setting and participants: </strong>Blood metabolome was measured in a sample of 89 patients with BD either under prophylactic lithium treatment (n = 47), and characterized as responders (R) or non-responders (NR), or with other mood stabilizers (MS, n = 42). For each patient plasma metabolome was measured with 1H-NMR and GC-MS. Data were investigated with multivariate analyses accounting for covariates.</p><p><strong>Results: </strong>Patients exposed to lithium or to other MS showed different, specific metabolic signatures, with different levels of metabolites belonging to pathways involved in glucose, pyruvate and glutamate metabolism, which were previously suggested to be implicated in BD and to be regulated by lithium. On the other hand, we were not able to identify significant differences in the metabolomic profile between responders and non-responders to lithium.</p><p><strong>Conclusions and relevance: </strong>Findings from this exploratory study suggest that patients treated with lithium show distinctive metabolomic biosignatures, specifically pointing to energy metabolism and mitochondria functioning, thus potentially suggesting possible biosignatures of mood stabilizing treatments.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identification of peripheral biomarkers through metabolomic analysis in patients with bipolar disorder treated with mood stabilizers: an exploratory study.\",\"authors\":\"Cristina Piras, Claudia Pisanu, Martina Spada, Anna Meloni, Donatella Congiu, Vanessa Palmas, Giovanni Severino, Raffaella Ardau, Caterina Chillotti, Martina Contu, Pasquale Paribello, Marco Pinna, Federico Suprani, Maria Del Zompo, Bernardo Carpiniello, Aldo Manzin, Mirko Manchia, Luigi Atzori, Alessio Squassina\",\"doi\":\"10.1093/ijnp/pyaf071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Bipolar disorder (BD) is mainly treated with mood stabilizers, among which lithium represents the gold standard. Despite its high clinical efficacy, the molecular players involved in lithium response and non-response remain partly unclear. Therefore, the identification of peripheral biomarkers would significantly improve the management of pharmacological interventions in BD.</p><p><strong>Objective and design: </strong>In this study we sought to investigate the blood metabolome in patients with BD to identify biosignatures of treatment with different mood stabilizers as well as possible biomarkers of response to lithium.</p><p><strong>Setting and participants: </strong>Blood metabolome was measured in a sample of 89 patients with BD either under prophylactic lithium treatment (n = 47), and characterized as responders (R) or non-responders (NR), or with other mood stabilizers (MS, n = 42). For each patient plasma metabolome was measured with 1H-NMR and GC-MS. Data were investigated with multivariate analyses accounting for covariates.</p><p><strong>Results: </strong>Patients exposed to lithium or to other MS showed different, specific metabolic signatures, with different levels of metabolites belonging to pathways involved in glucose, pyruvate and glutamate metabolism, which were previously suggested to be implicated in BD and to be regulated by lithium. On the other hand, we were not able to identify significant differences in the metabolomic profile between responders and non-responders to lithium.</p><p><strong>Conclusions and relevance: </strong>Findings from this exploratory study suggest that patients treated with lithium show distinctive metabolomic biosignatures, specifically pointing to energy metabolism and mitochondria functioning, thus potentially suggesting possible biosignatures of mood stabilizing treatments.</p>\",\"PeriodicalId\":14134,\"journal\":{\"name\":\"International Journal of Neuropsychopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Neuropsychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ijnp/pyaf071\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ijnp/pyaf071","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

重要性:双相情感障碍(BD)主要用情绪稳定剂治疗,其中锂是金标准。尽管其临床疗效很高,但参与锂反应和无反应的分子因素仍部分不清楚。因此,识别外周生物标志物将显著改善BD的药物干预管理。目的与设计:本研究旨在研究BD患者的血液代谢组,以确定不同心境稳定剂治疗的生物特征以及可能的锂反应生物标志物。环境和参与者:对89例BD患者的血液代谢组进行了测量,这些患者接受预防性锂治疗(n = 47),分为反应者(R)或无反应者(NR),或使用其他情绪稳定剂(MS, n = 42)。采用1H-NMR和GC-MS测定每位患者的血浆代谢组。对数据进行多变量分析,考虑协变量。结果:暴露于锂或其他MS的患者表现出不同的、特定的代谢特征,具有不同水平的代谢产物,属于葡萄糖、丙酮酸和谷氨酸代谢通路,这些通路先前被认为与BD有关,并受锂的调节。另一方面,我们无法确定对锂有反应者和无反应者之间代谢组学特征的显着差异。结论和相关性:这项探索性研究的结果表明,接受锂治疗的患者表现出独特的代谢组学生物特征,特别是指向能量代谢和线粒体功能,因此可能提示情绪稳定治疗的可能生物特征。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Identification of peripheral biomarkers through metabolomic analysis in patients with bipolar disorder treated with mood stabilizers: an exploratory study.

Importance: Bipolar disorder (BD) is mainly treated with mood stabilizers, among which lithium represents the gold standard. Despite its high clinical efficacy, the molecular players involved in lithium response and non-response remain partly unclear. Therefore, the identification of peripheral biomarkers would significantly improve the management of pharmacological interventions in BD.

Objective and design: In this study we sought to investigate the blood metabolome in patients with BD to identify biosignatures of treatment with different mood stabilizers as well as possible biomarkers of response to lithium.

Setting and participants: Blood metabolome was measured in a sample of 89 patients with BD either under prophylactic lithium treatment (n = 47), and characterized as responders (R) or non-responders (NR), or with other mood stabilizers (MS, n = 42). For each patient plasma metabolome was measured with 1H-NMR and GC-MS. Data were investigated with multivariate analyses accounting for covariates.

Results: Patients exposed to lithium or to other MS showed different, specific metabolic signatures, with different levels of metabolites belonging to pathways involved in glucose, pyruvate and glutamate metabolism, which were previously suggested to be implicated in BD and to be regulated by lithium. On the other hand, we were not able to identify significant differences in the metabolomic profile between responders and non-responders to lithium.

Conclusions and relevance: Findings from this exploratory study suggest that patients treated with lithium show distinctive metabolomic biosignatures, specifically pointing to energy metabolism and mitochondria functioning, thus potentially suggesting possible biosignatures of mood stabilizing treatments.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.40
自引率
2.10%
发文量
230
审稿时长
4-8 weeks
期刊介绍: The central focus of the journal is on research that advances understanding of existing and new neuropsychopharmacological agents including their mode of action and clinical application or provides insights into the biological basis of psychiatric disorders and thereby advances their pharmacological treatment. Such research may derive from the full spectrum of biological and psychological fields of inquiry encompassing classical and novel techniques in neuropsychopharmacology as well as strategies such as neuroimaging, genetics, psychoneuroendocrinology and neuropsychology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信